Ignite Creation Date:
2024-05-06 @ 8:07 PM
Last Modification Date:
2024-10-26 @ 3:21 PM
Study NCT ID:
NCT06265389
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-02-20
First Post:
2024-02-11
Brief Title:
Pentoxifylline as an Adjuvant Therapy in the Treatment of Pediatric Pneumonia A New Perspective of an Old Drug
Sponsor:
Tanta University
Organization:
Tanta University
Study Overview
Official Title:
Pentoxifylline as an Adjuvant Therapy in the Treatment of Pediatric Pneumonia A New Perspective of an Old Drug
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Pentoxifylline is a xanthine-derived commercially produced drug approved for the management of intermittent claudication in patients suffering from a chronic occlusive arterial disease of the limbs Pentoxifylline has been documented to display anti-inflammatory and immunomodulatory effects as well as some antithrombotic and antiviral effects This drug has also been shown to reduce lung fibrosis in patients with COVID-19 as well as to prevent thromboembolic events This work aims to assess the benefit of oral Pentoxifyllin supplementation in addition to standard antibiotic and other supportive therapy in the management of hospitalized children with community-acquired pneumonia
Detailed Description:
This is a randomized clinical trial study that will be carried out on 100 children with Community-acquired pneumonia admitted to the Pulmonology Unit Pediatric department
Group 1 Pentoxifylline group and group 2 Control group
Group 1 Pentoxifylline group and group 2 Control group
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None